vTv Therapeutics Inc. (VTVT) AI Stock Analysis

vTv Therapeutics Inc., headquartered in High Point, North Carolina, is a clinical-stage biopharmaceutical company focused on developing oral therapies for chronic conditions. Its pipeline is led by TTP399, a liver-selective glucokinase activator designed for type 1 diabetes, and HPP737, an oral PDE4 inhibitor targeting inflammatory diseases such as psoriasis. The company is also evaluating TTP273 for cystic fibrosis-related diabetes, HPP3033 for oxidative stress diseases, azeliragon for severe COVID-19 and select cancers, and HPP971 for renal indications. Additionally, it partners with firms like Reneo Pharmaceuticals, Inc. on HPP593, alongside collaborative agreements with Hangzhou Zhongmei Huadong Pharmaceutical, Newsoara Biopharma, JDRF International, and Novo Nordisk A/S.

Over the five-year span from FY2019 to FY2024, vTv Therapeutics registered a revenue CAGR of -18.1%. Annual revenue stood at $6.4M in FY2020 before falling to $4.0M in FY2021, $2.0M in FY2022, and $9,000 in FY2023. In FY2024, revenue rebounded to $1.0M, marking revenue growth of 11200.0%, while net income was -$18.5M and R&D expenses were $11.5M. The company remained unprofitable across these years, reporting net income of -$8.5M in FY2020 and -$20.2M in FY2023. For the trailing twelve months ended June 30, 2026, revenue reached $36.8M, with a profit margin of -12.9% and an EPS of -$0.72.

As of June 30, 2026, vTv Therapeutics reported $86.6M in cash and short-term investments, total assets of $87.6M, and shareholders' equity of $78.6M. Liquidity remained elevated with a current ratio of 12.48. Operating cash flow stood at -$25.3M in FY2024, matching free cash flow of -$25.3M, following free cash flow of -$19.1M in FY2023 and -$15.3M in FY2022. Over the five-year period through FY2025, the company's share count expanded by 643.2%.

At the last close of $26.54 on October 16, 2026, vTv Therapeutics carried a market cap of $104.9M and an enterprise value of $22.8M. The company trades at a price-to-sales multiple of 2.8x, below the 4.1x median of its US-listed Healthcare peers. Its EV-to-revenue ratio is 0.6x, and its price-to-book ratio is 1.5x. The stock gained 27.7% over the trailing one-year period, outpacing the S&P 500 return of 16.8%. Over five years, its return of -54.9% trailed the S&P 500 gain of 83.0%.

Consensus coverage includes 7 Strong Buy ratings and zero Buy, Hold, Sell, or Strong Sell ratings. Analysts have established a mean price target of $56.00, representing upside of 111.0% from the last close of $26.54. For the fiscal year ending December 31, 2026, consensus estimates model revenue of $30.7M and an EPS of -$1.71. For the following fiscal year, 7 analysts project revenue of $0 and an EPS of -$4.38. The company exceeded EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 5, 2026.

This page is an AI-written research summary of vTv Therapeutics Inc. (VTVT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VTVT income statement, VTVT balance sheet, VTVT key metrics, VTVT analyst forecast, VTVT chart. See the VTVT stock overview for the latest quote and news.